Literature DB >> 18591515

The use of highly active retroviral therapy to reduce HIV incidence at the population level.

Aranka Anema1, Evan Wood, Julio S G Montaner.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18591515      PMCID： PMC2464478          DOI： 10.1503/cmaj.071809

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  12 in total

1.  Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco.

Authors:  Mitchell H Katz; Sandra K Schwarcz; Timothy A Kellogg; Jeffrey D Klausner; James W Dilley; Steven Gibson; William McFarland
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

2.  Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV.

Authors:  Jesús Castilla; Jorge Del Romero; Victoria Hernando; Beatriz Marincovich; Soledad García; Carmen Rodríguez
Journal:  J Acquir Immune Defic Syndr       Date:  2005-09-01       Impact factor: 3.731

Review 3.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

Review 4.  Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.

Authors:  Myron S Cohen; Cynthia Gay; Angela D M Kashuba; Sally Blower; Lynn Paxton
Journal:  Ann Intern Med       Date:  2007-04-17       Impact factor: 25.391

5.  Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand.

Authors:  Sodsai Tovanabutra; Valerie Robison; Jeerang Wongtrakul; Supaluk Sennum; Vinai Suriyanon; Duangnapa Kingkeow; Surinda Kawichai; Praijitr Tanan; Ann Duerr; Kenrad E Nelson
Journal:  J Acquir Immune Defic Syndr       Date:  2002-03-01       Impact factor: 3.731

6.  Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings.

Authors:  Ume L Abbas; Roy M Anderson; John W Mellors
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-15       Impact factor: 3.731

7.  Infrequent transmission of HIV-1 drug-resistant variants.

Authors:  Sabine Yerly; Stéphanie Jost; Amalio Telenti; Markus Flepp; Laurent Kaiser; Jean-Philippe Chave; Pietro Vernazza; Manuel Battegay; Hansjakob Furrer; Bruno Chanzy; Philippe Burgisser; Martin Rickenbach; Martin Gebhardt; Marie-Charlotte Bernard; Thomas Perneger; Bernard Hirschel; Luc Perrin
Journal:  Antivir Ther       Date:  2004-06

8.  Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review.

Authors:  Nicole Crepaz; Trevor A Hart; Gary Marks
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

Review 9.  Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.

Authors:  P Brocklehurst; J Volmink
Journal:  Cochrane Database Syst Rev       Date:  2002

10.  Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

Authors:  Viviane D Lima; Karissa Johnston; Robert S Hogg; Adrian R Levy; P Richard Harrigan; Aranka Anema; Julio S G Montaner
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226
View more
  4 in total

1.  Comprehensive Approaches to the Diagnosis and Treatment of HIV Infection in the Community: Can "Seek and Treat" Really Deliver?

Authors:  Brian Conway; Harout Tossonian
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

2.  How HIV treatment could result in effective prevention.

Authors:  Kartik K Venkatesh; Mark N Lurie; Kenneth H Mayer
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

3.  Expanded Highly Active Antiretroviral Therapy Coverage - A Powerful Strategy to Curb Progression to AIDS, Death and New Infections.

Authors:  Aranka Anema; Viviane D Lima; Karissa Johnston; Adrian Levy; Julio Sg Montaner
Journal:  Eur Infect Dis       Date:  2009

4.  First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.

Authors:  Peter A Anton; Terry Saunders; Julie Elliott; Elena Khanukhova; Robert Dennis; Amy Adler; Galen Cortina; Karen Tanner; John Boscardin; William G Cumberland; Ying Zhou; Ana Ventuneac; Alex Carballo-Diéguez; Lorna Rabe; Timothy McCormick; Henry Gabelnick; Christine Mauck; Ian McGowan
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.